Alembic Pharmaceuticals share price falls over 4 percent in early trade on March 16 after the company received 4 observations from the USFDA.
US Food and Drug Administration (USFDA) has conducted an inspection at the company's general oral solid formulation facility located at Panelav from March 9 to 13, 2020.
This was a scheduled inspection and at the end of the inspection, the USFDA issued a Form 483 with four procedural observations.
None of the observations are related to data integrity or repetitive in nature, company said in release.
The company will provide comprehensive corrective action report to address each observation.
The company is committed to maintaining highest quality standards that meet USFDA standards, it added.
At 09:27 hrs Alembic Pharmaceuticals was quoting at Rs 550, down Rs 25, or 4.35 percent on the BSE.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.